PT  - JOURNAL ARTICLE
AU  - James C. Waddington
AU  - Orla Coleman
AU  - Philip J. Mease
AU  - Vinod Chandran
AU  - Denis O’Sullivan
AU  - Oliver FitzGerald
AU  - Stephen R. Pennington
TI  - Basic Science Session 1. Biomarkers for Psoriatic Arthritis Treatment Response and Joint Damage Progression: An Update on 2 Industry-GRAPPA Projects
AID  - 10.3899/jrheum.211320
DP  - 2022 Jun 01
TA  - The Journal of Rheumatology
PG  - 13--15
VI  - 49
IP  - 6 Suppl 1
4099  - http://www.jrheum.org/content/49/6_Suppl_1/13.short
4100  - http://www.jrheum.org/content/49/6_Suppl_1/13.full
SO  - J Rheumatol2022 Jun 01; 49
AB  - The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has identified several priority areas for biomarker development, including biomarkers to predict at baseline which patients may progress to develop joint damage and whether a patient will respond to a specific targeted therapy. Two industry-GRAPPA projects were initiated in 2020 on these biomarker research areas: (1) the Pfizer-GRAPPA project, focused on biomarkers of treatment response to tofacitinib in the Oral Psoriatic Arthritis TriaL program; and (2) the Lilly-GRAPPA project, focused on biomarkers of damage in the ixekizumab SPIRIT-P1 randomized controlled trial. Preliminary results from these 2 projects were presented by the GRAPPA team, with both studies showing promising initial results. Data from these studies will be published when the studies have been completed. Large-scale validation studies are required and are under discussion.